- $550.64m
- $909.07m
- $573.28m
- 66
- 53
- 52
- 59
Annual cashflow statement for Bioventus, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | 14.7 | 9.59 | -213 | -196 | -43.8 |
| Depreciation | |||||
| Deferred Taxes | |||||
| Non-Cash Items | 13.6 | 1.56 | 200 | 159 | 50.2 |
| Discontinued Operations | |||||
| Unusual Items | |||||
| Equity in Net Earnings/Losses | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | 15.3 | -13.3 | -14.5 | -3.18 | -11.8 |
| Change in Accounts Receivable | |||||
| Change in Inventories | |||||
| Change in Payable / Accrued Expenses | |||||
| Net Change in Other Assets & Liabilities | |||||
| Cash from Operating Activities | 71.8 | 23 | -13.5 | 15.3 | 38.8 |
| Capital Expenditures | -4.09 | -7.37 | -10 | -7.36 | -1.01 |
| Purchase of Fixed Assets | |||||
| Other Investing Cash Flow Items | -16.4 | -276 | -106 | 23.2 | 24 |
| Acquisition of Business | |||||
| Sale of Business | |||||
| Other Investing Cash Flow | |||||
| Cash from Investing Activities | -20.5 | -284 | -116 | 15.8 | 23 |
| Financing Cash Flow Items | -19.6 | -2.24 | -3.37 | -4.17 | 2.56 |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | -29.6 | 273 | 62.1 | -26.7 | -54.6 |
| Foreign Exchange Effects | |||||
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | 22.3 | 12.4 | -67.4 | 5.13 | 4.62 |